Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clobetasol propionate ophthalmic nanoemulsion - Salvat

Next Previous
Search
Drug Profile

Clobetasol propionate ophthalmic nanoemulsion - Salvat

Alternative Names: SVT-15473

Latest Information Update: 16 Oct 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SALVAT
  • Class Anti-inflammatories; Antipsoriatics; Antiulcers; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Halogenated hydrocarbons; Propionates; Small molecules
  • Mechanism of Action Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Postoperative inflammation; Postoperative pain
  • No development reported Eye disorders

Most Recent Events

  • 16 Oct 2022 NDR Batch#24: QC feedbacks incorporated
  • 06 Oct 2022 No development reported - Phase-II for Eye disorders in Spain (Ophthalmic) (Salvat pipeline, October 2022)
  • 05 Oct 2022 Phase-III clinical trials in Postoperative inflammation (In children, In infants, In neonates) in Spain (Ophthalmic) (EudraCT2022-000624-37)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top